SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
22
10
2021
received:
10
07
2021
accepted:
16
11
2021
pubmed:
23
11
2021
medline:
29
4
2022
entrez:
22
11
2021
Statut:
ppublish
Résumé
The relative risk of SARS-CoV-2 infection and COVID-19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of SARS-CoV-2 infection in those with RMDs and describe clinical outcomes of COVID-19 in these patients. We conducted a systematic literature review using 14 databases from January 1, 2019 to February 13, 2021. We included observational studies and experimental trials in RMD patients that described comparative rates of SARS-CoV-2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation, or death attributed to COVID-19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effects models. Of the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta-analyses, we identified an increased prevalence of SARS-CoV-2 infection in patients with an RMD (RR 1.53 [95% CI 1.16-2.01]) compared to the general population. The odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08-2.80]). In a smaller number of studies, the adjusted risk of outcomes related to COVID-19 was assessed, and the results varied; some studies demonstrated an increased risk while other studies showed no difference in risk in patients with an RMD compared to those without an RMD. Patients with RMDs have higher rates of SARS-CoV-2 infection and an increased mortality rate.
Identifiants
pubmed: 34807517
doi: 10.1002/art.42030
pmc: PMC9011807
mid: NIHMS1774073
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
766-775Subventions
Organisme : NIAMS NIH HHS
ID : K23 AR073334
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR073752
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR048522
Pays : United States
Informations de copyright
© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
ACR Open Rheumatol. 2021 May;3(5):333-340
pubmed: 33856739
Ann Rheum Dis. 2021 Sep;80(9):1137-1146
pubmed: 34049860
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI59-SI67
pubmed: 33369663
Rheumatology (Oxford). 2013 Jan;52(1):53-61
pubmed: 23192911
Ann Rheum Dis. 2020 Sep;79(9):1156-1162
pubmed: 32457048
Arthritis Rheumatol. 2021 Jan;73(1):48-52
pubmed: 32767527
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Ann Rheum Dis. 2020 Sep;79(9):1170-1173
pubmed: 32532753
Lancet Rheumatol. 2021 May;3(5):e317-e318
pubmed: 33907738
Psychol Health Med. 2017 Oct;22(9):1105-1117
pubmed: 28100062
Epidemiol Infect. 2020 Jul 27;148:e163
pubmed: 32713371
Ann Rheum Dis. 2021 May;80(5):660-666
pubmed: 33257496
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483
Ann Intern Med. 2021 May;174(5):613-621
pubmed: 33460330
Rheumatol Int. 2021 May;41(5):851-861
pubmed: 33687528
JAMA Netw Open. 2021 May 3;4(5):e218828
pubmed: 33938933
Arthritis Rheumatol. 2021 Jun;73(6):914-920
pubmed: 33305544
Clin Rheumatol. 2021 Apr;40(4):1575-1579
pubmed: 33174109
Joint Bone Spine. 2021 May;88(3):105131
pubmed: 33486110
Ann Rheum Dis. 2020 Dec 2;:
pubmed: 33268442
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
RMD Open. 2021 Jan;7(1):
pubmed: 33479021
J Clin Epidemiol. 2018 May;97:26-34
pubmed: 29248724
Autoimmun Rev. 2021 Apr;20(4):102778
pubmed: 33609804
Clin Exp Rheumatol. 2021 Mar-Apr;39(2):442-443
pubmed: 33025882
Rheumatol Adv Pract. 2021 May 13;5(2):rkab031
pubmed: 34622123
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Lancet Rheumatol. 2020 Sep;2(9):e557-e564
pubmed: 32838309
Arthritis Rheumatol. 2021 Jan;73(1):36-47
pubmed: 32741139
PLoS Med. 2020 Sep 10;17(9):e1003321
pubmed: 32911500
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Arthritis Rheumatol. 2021 Jul;73(7):1108-1123
pubmed: 34101376
Ann Rheum Dis. 2020 Dec;79(12):1544-1549
pubmed: 32796045
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Clin Microbiol Infect. 2021 Apr;27(4):611-617
pubmed: 33316402
Ann Rheum Dis. 2020 Oct 13;:
pubmed: 33051220
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328